SUMMARY

Scope of the submission
The MS addresses the scope requested. In essence this was to address the effectiveness and cost-effectiveness of azacitidine relative conventional care regimens, particularly BSC, LDC and SDC, in patients with higher risk MDS, CMML and AML with 20-30% blasts on the outcomes of survival, time to progression to AML, adverse events and HRQoL.
Summary of submitted clinical effectiveness evidence
The blasts.
The AZA-001 study showed that:
• The median overall survival was 24.5 months on azacitidine, compared with 15.0 months in the CCR group (p=0.0001)
• The response rates were low (complete remission 17% aza vs 8%
CCR)
• The median time to transformation to AML was greater in the azacitidine group (17.8 versus 11.5 months; p<0.0001).
• Of patients who were RBC transfusion-dependent at baseline, 45% of those on azacitidine became RBC transfusion-independent during the treatment period, compared with 11.8% in the CCR group (p<0.0001)
Summary of submitted cost effectiveness evidence
Estimates of cost per QALY gained for azacitidine in comparison with BSC, LDC and SDC are provided.
Commentary on the robustness of submitted evidence
Strengths
Concerning the evidence on clinical effectiveness the evidence was based on an adequately powered RCT, study AZA-001 reported by Fenaux et al in Lancet Oncology in 2009. The trial was registered and a protocol for the trial was available. The effects on survival, time to progression to AML, independence from transfusion and reduction in infections requiring intravenous antibiotics were clinically important and unlikely to have been explained by chance alone. There was no evidence that these benefits were substantially off-set by adverse events.
Weaknesses
Concerning clinical effectiveness the AZA-001 study was open to bias, particularly from lack of blinding and uncertainty about losses to follow-up. In addition there was no direct evidence on impact on HRQoL. There is no evidence for differences in effects between investigator pre-selected treatment groups.
The overwhelming observation however was the errors in the model which were sufficiently severe and numerous that the credibility of the estimates of cost-effectiveness provided in the MS were completely undermined.
Areas of uncertainty
The credibility of the estimates of cost-effectiveness is the pre-dominant issue.
Even if the model is corrected further areas of uncertainty will remain such as:
• The degree to which the size of effects may have been overestimated because of the observed biases 
Key issues
Although there are concerns about the clinical effectiveness evidence and the parameters used in the model, the over-riding issue is the fundamental validity of the estimates of cost-effectiveness presented in the MS.
BACKGROUND
Critique of manufacturer's description of underlying health problem
The key points concerning the health problem, as indicated in the final scope 
Critique of manufacturer's overview of current service provision
The key points indicated in the scope are that the mainstay of treatment for MDS is best supportive care (transfusions, growth factors, antibiotics) to control the symptoms of bone marrow failure, and low-dose standard chemotherapy for some patients. Stem cell transplant is not an option for the majority of patients since the patients' age and/or co morbidities usually precludes this treatment option.
The manufacturer's portrayal of the current treatment options are consistent with this view. The MS often refers to standard dose chemotherapy as compared to low dose chemotherapy. To avoid confusion it needs to be recognised that standard dose chemotherapy is actually intensive, and indeed in the main trial providing evidence on effectiveness 1 is referred to as "intensive chemotherapy". The very limited use of high dose chemotherapy, particularly in patients over 65 years of age needs emphasis.
Critique of manufacturer's definition of decision problem
Indicated scope
Intervention Azacitidine
Population
Adults who are not eligible for haematopoietic stem cell transplantation with higher-risk (IPSS intermediate-II risk and high-risk) myelodysplastic syndromes, chronic myelomonocytic leukaemia, or acute myeloid leukaemia (<30% blasts)
Comparators
• best supportive care (such as blood transfusions, erythropoietin and granulocytecolony stimulating factor, with infection prophylaxis)
• chemotherapy (such as cytarabine and anthracyclines)-low and high dose
Outcomes
The outcome measures to be considered include:
• overall survival
• progression-free survival (including time to transformation to AML or death)
• response rates, including haematologic response and improvement
• blood-transfusion independence
• infections requiring IV therapy
• adverse effects of treatment
• health-related quality of life.
Economic analysis
The reference case stipulates that the cost effectiveness of treatments should be expressed in terms of incremental cost per quality-adjusted life year. The reference case stipulates that the time horizon for estimating clinical and cost effectiveness should be sufficiently long to reflect any differences in costs or outcomes between the technologies being compared. Costs will be considered from an NHS and Personal Social Services perspective.
Other considerations
If the evidence allows, consideration will be given to the subgroup of patients with chromosome 7 abnormalities. Guidance will only be issued in accordance with the marketing authorisation.
Population
The population of interest in the industry submission is consistent with the scope, both of which in turn coincide with the market authorisation.
Intervention
The submission is again consistent with the scope. The marketing authorisation indicates the dose and route of azacitidine to be 75mg/m 2
Comparators
subcutaneously daily for 7 days followed by a rest period of 21 days (28 day treatment cycle). It is recommended that patients be treated for a minimum of 6 cycles, continuing for as long as the patient continues to benefit or until disease progression.
The comparators used in the manufacturer submission are consistent with the scope.
Outcomes
The outcomes used in the manufacturer submission are consistent with the scope.
Time frame
The time frame adopted is consistent with the scope, with attempts in the economic model to extrapolate to a lifetime time horizon.
Other relevant factors
The submission considers the main genetic sub-group identified, chromosome 7 abnormalities, especially -7/del(7q)
CLINICAL EFFECTIVENESS
Critique of manufacturer's approach
Description of manufacturers search strategy and comment on
whether the search strategy was appropriate.
The two main searches for studies on azacitidine and its comparators appear generally comprehensive and included the following databases:
The searches were conducted up to March 2009. The searches were examined by an experienced information specialist in the ERG who spotted no major errors, but several minor problems:
• The search strategy for only one database is detailed in full. It appears to be for MEDLINE but this is not stated.
• The search for Azacitidine is constructed on text and index terms capturing the intervention and one of the conditions of interest (Myelodysplastic syndrome). Terms for chronic myelomonocytic leukaemia and acute myeloid leukaemia are not represented therefore one would expect these studies to have been missed.
• The search for the comparator treatments is constructed on text and index terms capturing the interventions, conditions and a study design filter for randomised controlled trials.
• In the search for comparator treatments, while some text word terms have been searched in the title and abstract fields and also mapped to an available subject term, others have been searched in the title field only. Searching text words in all available text fields would have yielded a more comprehensive search.
• Trials registers were not searched therefore some ongoing studies may have been overlooked.
• Searching activity appears to have been limited to bibliographic databases, so as well as on-going studies being under-represented, unpublished studies may have been under-represented too.
A certain amount of re-running of searches was undertaken within the limits of the time available, as indicated in Appendix 1. No additional studies were identified.
A request for further information was made concerning on-going studies and the manufacturer provided further information indicated and summarised in a later section.
Statement of the inclusion/exclusion criteria used in the study
selection and comment on whether they were appropriate.
The inclusion criteria were provided in 6.1.2 and 10.2.6 in the manufacturer submission. They are clearly stated and consistent with the decision problem.
An important criterion is that studies with less than 50% of participants in the intermediate-2 and high risk IPSS, CMML (10-29% blasts) and AML (20-30% blasts) are excluded and has an important consequence which is discussed later. There is no information on the number of reviewers who screened and performed the inclusion/exclusion decisions, and no copies of the forms which were used to do this. Use of routine database commands to exclude studies deserves clarification (p19) and the high proportion of hits excluded by this means (1792/2366, 76%) is a concern. 4.1. 3 Table of identified A request for further information was made to the manufacturer for the subgroup data relating to higher risk patients in CALGB-9221. They were able to do this for survival, but were unable to disaggregate the data for HRQoL results.
Details of any relevant studies that were not included in the submission?
We identified no additional completed RCTs.
The MS presented a confusing account of on-going studies, concentrating on follow-up publications of existing completed studies like AZA-001. A request for further information elicited a list of 15 on-going studies. Only one of these was a phase III RCT and none appeared relevant to this appraisal based on the detail supplied.
Description and critique of manufacturers approach to validity assessment
There was no structured assessment of validity as encountered in most systematic reviews. This was particularly apparent for the included studies in the comparator section of the review. Most of the key issues concerning threats to validity were touched on in 6.3 of the MS.
Because of the central importance of AZA-001 it was full re-appraised by the ERG as part of this appraisal, taking advantage of responses to requests for clarification from the manufacturer. This detailed appraisal is provided in Appendix 2.
Description and critique of manufacturers outcome selection
The MS reports all outcomes measured in AZA-001. This covers all the outcomes suggested in the final scope for this STA with the exception of HRQoL. Outcomes which are likely to impact on HRQoL, like freedom from transfusion and rates of infection requiring intravenous antibiotics are reported. However it is clear that there is no direct research evidence supporting the claim that "azacitidine results in a marked improvement in patient well-being" in the population of interest in this STA. The manufacturer confirms this fact in their response to a request for clarification concerning the impact of aza on HRQoL (response B3).
Describe and critique the statistical approach used
For azacitidine's effectiveness, meta-analysis is unnecessary because there is only a single included RCT.
For the comparators, although there is no pooling, the approach taken is to consider the arms of the RCTs included in isolation, effectively breaking randomisation. Most of the conclusions based on this part of the review thus need to be treated with caution. Fortunately these conclusions do not contribute substantially to the overall conclusions and do not feed into the economic modelling.
Summary statement
Although the approach to reviewing the evidence on clinical effectiveness falls short of the standards suggested by QUOROM, the evidence in the MS on azacitidine generally appears complete and relevant to the decision problem.
The exception is data on impact of aza on HRQoL. There is an attempt to suggest that data from the excluded trial CALGB-9221 provides such evidence. However the reason for exclusion, <50% of participants in higher risk conditions, invalidates the results on HRQoL as equally as on survival and time to progression to AML.
The evidence on comparators, although complete, does not contribute greatly to decision problem and can be largely disregarded.
Summary of submitted evidence
Summary of results
The executive summary offers the following synopsis of the evidence on clinical effectiveness, which as indicated is mainly and appropriately derived from the AZA-001 study:
Median overall survival was 24.5 months on azacitidine, compared with 15.0 months in the CCR group (p=0.0001). In a supportive analysis, this survival advantage was observed across all IPSS cytogenetic subgroups, in patients with -7/del(7q) and in elderly patients with AML. The overall survival gain was observed despite relatively low response rates. Analysis suggests that achievement of complete remission is not essential to improve survival. Partial remission and haematological improvement were also associated with survival benefit (see Section 6.4.1). Although seven, relevant, comparator, Phase III, randomised controlled trials were identified, three of which included a BSC arm, no meta-analysis could be carried out and none of the therapies reviewed showed a better median overall survival, either for azacitidine or BSC, than those reported in Study AZA-001 (see Sections 6.4.1 and 6.5).
The survival curves for the primary outcome, overall survival are reproduced below. It is important to note where this figure is reproduced in black & white that in the first few months after treatment, the aza curve is below that for the CCR, only crossing over to indicate improved survival for aza after 4 months.
Consideration of the results by the investigator pre-selected groups (BSC, LDC and SDC) is also emphasised and is particularly critical in the context of the economic model. The overall AZA-001 trial result in comparison with those in each of the investigator pre-selected groups are indicated in the 
Critique of submitted evidence syntheses
As indicated in the ERG critical appraisal of Fenaux et al, Appendix 2, the evidence for the effectiveness of aza relative to CCR is reasonably robust with three provisos: 
Summary
There is some possibility of bias concerning all estimates of the effect of aza relative to CCR (consisting of BSC, LDC or SDC, depending on circumstances). It would be reasonable to consider the possibility that estimates of effect had been over estimated in sensitivity analyses in the economic model.
In addition great caution should be exercised concerning the interpretation of the evidence presented on impact on HRQoL and difference in effect between different investigator pre-selected groups.
ECONOMIC EVALUATION
Manufacturers review of previous economic evaluation
The MS undertook a separate search for evidence on cost-effectiveness. Five potential studies were identified, as listed in Table 7 .1 in the MS. All were excluded although the criteria used to screen or include/exclude were not given.
The search strategy was appraised by the ERG information specialist. The following issues were noted:
• The search is constructed on text and index terms for the conditions of interest and 'the database was then searched for any reference with the terms: cost effectiveness; cost -effectiveness; economic and economics'.
Since no further details are given it is difficult to assess the quality of the search or the likelihood of references having been missed. Also, the search is impossible to replicate.
This suggests that relevant studies may have been overlooked.
The search strategies indicated in Appendix 1 were run by the ERG, but no additional included economic evaluations were identified.
Overview of manufacturer's economic evaluation
The manufacturer provided an economic submission in both report (Word) The major clarifications requested by the ERG related to specific coding errors and their resolution. These include those preventing survival data from being used in the model. These took the form of IF statements which ensured that the survival data was not used at critical points, and broken links that prevented it from being used when these first errors were resolved. Other major issues related to the apparent non-discounting of costs and the nonprovision of critical information, including the uncertainty attached to the time spent in acute myeloid leukaemia and important covariances between parameters characterising the survival data. In addition to these clarifications, the ERG noted that the model had important functionality removed, particularly as regards the analysis of subgroups.
Results included in manufacturer's submission
The results of the economic analyses as presented in the MS are summarised in Table 7 .17 of the submission (see below). It should be emphasised that the ERG's strong view is that no weight can be placed on the numerical values of the ICERs because of the severity of the problems noted above.
Comment on validity of results presented with reference to methodology used
The validity of the results is severely undermined by the problems with the 
Summary of uncertainties and issues
The flaws found by the ERG in this model were of a sufficient number and severity that no confidence can be placed in the model results at present.
Beyond this however, even if a credible model were produced substantial uncertainty would remain concerning effectiveness, quality of life and cost parameters whose impact would need to be fully investigated anew in the revised model. Because of the potential to mislead in the presence of serious concerns about the basic validity of the current MS model, the outputs of the last three activities have not been presented in this report. It is intended that they will be re-applied to a corrected MS model when supplied.
Discussion
Summary of clinical effectiveness issues
The evidence on clinical effectiveness was based on an adequately powered RCT, study AZA-001 reported by Fenaux et al 1 in Lancet Oncology in 2009.
The trial was registered and a protocol for the trial was available. The effects on survival, time to progression to AML, independence from transfusion and reduction in infections requiring intravenous antibiotics were clinically important and unlikely to have been explained by chance alone. There was no evidence that these benefits were substantially off-set by adverse events.
However, the AZA-001 study was open to bias, particularly from lack of blinding and uncertainty about losses to follow-up. In addition there was no direct evidence on impact on HRQoL and here is no evidence for differences in effects between investigator pre-selected treatment groups.
Summary of cost effectiveness issues
The overwhelming issue was the errors in the model which were sufficiently severe and numerous that the credibility of the estimates of cost-effectiveness provided in the MS were completely undermined.
There are residual issues concerning the model parameters, but these cannot be sensibly addressed until a credible model has been produced.
Other issues
The logistic problem of delivering a seven day treatment cycle of azacitidine where hospital pharmacies are generally closed at weekends was an important issue raised by our clinical adviser.
Implications for research
Capturing the impact of azacitidine on HRQoL has clearly been a challenge suggesting that there may need to be further research specifically on the effect of azacitidine on quality of life, but also generally on how to capture improvements in health in MDS, possibly through the development of new disease specific QoL tools. • Induction -either iv daunorubicin 45-60 mg/m per day by continuous intravenous (iv)infusion for 7 days PLUS 2 per day for 3 days or iv idarubicin 9-12 mg/m 2 per day for 3 days or iv mitoxantrone 8-12 mg/m 2 • Consolidation for those who achieved complete or partial remission after induction -one or two courses of same drugs used for induction at reduced dosages per day for 3 days All conventional care arms, not just the best supportive care option, could receive elements of best supportive care with the exception of the eythropoeitin stimulating agents.
It was clarified in a request for further information (A6) that there were no centrally defined protocols for giving blood products, other than those that might be operating in the investigation centres.
Outcomes -• (Primary) Overall survival • Time to transformation to acute myeloid leukaemia (AML) • Haematological response • Improvement assessed with IWG 2000 criteria for myelodysplastic syndromes • Independence from red-blood-cell transfusions for 56 consecutive days or more • Number of infections requiring intravenous antibiotics • Occurrence of adverse events Length of follow-up was until 12 months after the entry of the last patient into the trial. Analysis was on the basis of intention-to-treat, except for safety analyses where a participant had to have had at least one dose of the intervention and one or more safety assessments thereafter. Outcomes were general assessed by site investigators. There was central review of pathology and all cytogenetic data.
Outcomes stated are consistent with outcomes listed in trial registry ClinicalTrials.gov for NCT00071799. It was clarified in response to request for further information (item A4) that the order within each block was randomly assigned and that there were 4 strata (RAEB/Int-2;RAEB/High;RAEB-T/Int-2;RAEB-T/High).
Method of randomisation -allocation concealment:
Randomisation centrally by phone.
Baseline equivalence:
Fully reported in Table 1 .
Good balance between Intervention and Conventional Care groups
This balance was not maintained for the investigator pre-selected sub-groups.
In particular in the participants pre-selected for intensive chemotherapy there was and excess of poorer prognosis patients based on IPSS, karyotype risk and WHO classification in the group actually receiving intensive chemotherapy relative to the group receiving azacitidine. Results in this subgroup are thus likely to have been biased towards azacitidine.
Blinding:
Explicitly open label.
Outcomes measured by site investigators. Only pathology and cytogenetics were reviewed centrally.
Amplified in response to request for further information (A5) The gold standard is to blind all aspects of a study. However, in certain protocols this is not feasible because of patient condition and/or the nature of the study. In Study AZA-001 certain subjective evaluations (eligibility to enter the study and haematological response, but not haematological improvement) were made by an independent central reviewer and local evaluations by the investigator, which could have introduced bias. Nevertheless, the study was blinded as far as was possible to eliminate further bias. The central pathology reviewer and adjudicators as well as the central cytogenetic reviewers were blinded to patient treatment assignment. Additionally, the Independent Review Committee which confirmed FAB and WHO MDS diagnoses, IPSS classifications and International Working Group response findings was blinded to patient information and investigative site.
Loss to follow-up:
These are not clear from journal article This was clarified in response to request for further information A7. The reply below was marked as commercially in confidence. 0  5  10  15  20  25  30  35  40  Number at risk  179  152  130  85  52  30  10  1 We have assumed that the major contribution to the category ************************************ is reaching the end of the trial without an event occurring. In addition the additional information indicates that ****************************************************** **************************** and that the reasons for this, such as *********************, ***************************************************** may be associated with higher death rates. If these participants were included there may have been a reduction in the stated effect of azacitidine.  AZA (n=30) median 13.1 months (IQR 3.9 to 24.5)  Conventional (n=27) median 4.6 months (IQR 2.9 to 9.3)  HR 0.34 (95% CI 0.17 to 0.67) (stratified log rank p=0.0017) o In the investigator preselected sub-groups the differences were:
Results
 AZA vs best supportive care 9.6 months, p=0.0045  AZA vs low dose chemotherapy 9.2 months, p=0.0006  AZA vs intensive chemotherapy 9. 
Unclear Additional information provided on a commercially in confidence basis CONCLUSION
The study is open to bias from lack of blinding. This is not a criticism of the triallists, as making a trial such as this blinded may be virtually impossible. However, the absence of blinding may suggest some caution is required in interpretation as this consideration would indicate that the measured size of effect could be an overestimate. Some bias may also have been introduced through ************ The validity of estimates of effect concerning the investigator specified preselected treatment groups needs to be interpreted particularly cautiously in view of the small size of the sub-groups, particularly the intensive chemotherapy group. This is reinforced by the noted imbalance in the baseline characteristics. loss to followup, which emerges from the cic data supplied in request to further information about loss to follow-up.
